Month: September 2020

In preparation for launching Beyond Tobacco™ cigarettes, which is set to take place in Q4 2020, the Company has completed and filed a U.S. patent application for a proprietary refinement process of base cigarette material, which contributes to the tobacco flavour and aroma of Beyond Tobacco™ cigarettes, which contain no tobacco whatsoever. Incumbent cigarette producers such as the ‘Big Tobacco’ firms are known to apply for and hold as many as several thousand patents to protect their rights to innovations and processes, which has become especially common with the advent of new categories such as smokeless and reduced risk products. Because the flavour and aroma of Beyond Tobacco™ cigarettes are defining features of the product, it has become a priority for Taat to complete this patent application so that the Company can retain rights...

SAN CLEMENTE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced that Company management will present virtually at the Morgan Stanley 18th Annual Global Healthcare Conference, held on September 14-18, 2020.ICU Medical’s presentation will be on Thursday, September 17, 2020 at 12:30 PM Eastern Time.The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay.About ICU Medical, Inc.ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medical products used in infusion...

Ares Genetics nominated for the 40th Austrian Innovation Award by Federal Ministry for Digital and Economic AffairsARESupa – Universal Pathogenome Assay nominated by expert jury for Austria’s most distinguished innovation awardVIENNA, Austria, and GAITHERSBURG, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has been nominated for the 40th Austrian Innovation Award (Ref. 1).Ares Genetics has been selected by an expert jury as one of six finalists for its artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST) marketed under the brand name ARESupa – Universal Pathogenome Assay. The Austrian Innovation Award is awarded by the Federal Ministry for Digital...

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE:BBM) (OTCQB: BBRRF) (FRA: 1OA), (the “Company” or “Blueberries“), a Latin American, licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that Camilo Villalba, Co-founder & Chief Executive Office, will present live at VirtualInvestorConferences.com on September 10th.  This will be a live, interactive online event where investors are invited to ask Mr. Villalba questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.Learn more about the event at www.virtualinvestorconferences.com.Recent...

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that enrollment and dosing in its Phase 1/2 clinical trial for MRT5005 in cystic fibrosis (CF) has resumed, with multiple clinical sites being open for enrollment. In March 2020, the Company had announced a pause to enrollment and dosing in the clinical trial in response to the COVID-19 pandemic. The Company plans to provide updated timing on the expected interim data readout of the additional single-ascending dose (SAD) group and the multiple-ascending dose (MAD) portion of the clinical trial at a later date.“We are pleased that enrollment and dosing in the...

Data highlights socio-demographic and clinical disparities to help raise awareness of health inequities and inform future treatment planningReal-world data from MS PATHS identifies clinically relevant benchmarks to predict employment status among people with multiple sclerosis (MS)Biogen is developing digital tools and technologies, such as CogEval® and Konectom™, to facilitate more personalized decisions in MS care with the goal of improving outcomes  CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced findings from two large, real-world studies that provide insight into the clinical and health disparities that exist for people living with multiple sclerosis (MS). These data, from MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) and the North American Registry...

REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming 2nd Annual RAS-Targeted Drug Development Conference being held virtually September 14-16, 2020. Steve Kelsey, M.D., president, research and development, and Jan Smith, Ph.D., senior vice president, biology, will be featured speakers during the digital event.Details of Revolution Medicines’ participation in the 2nd Annual RAS-Targeted Drug Development Conference are as follows:Additional information on the 2nd Annual RAS-Targeted Drug Development Conference is available through the conference website at https://ras-drugdevelopment.com/About...

VANCOUVER, Sept. 08, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for BetterLife and to broaden the Company’s reach within the investment community.Hybrid has agreed to comply with all applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”) in providing the services.“We are happy to be working with Hybrid to help increase our investor awareness in Canada” said Dr. Ahmad Doroudian, CEO of BetterLife. “BetterLife has ambitious plans and a bright future. As we move forward with our pipeline of treatments, in particular...